Blume Capital Management Inc. Has $303,000 Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

Blume Capital Management Inc. trimmed its holdings in Merck & Co., Inc. (NYSE:MRKFree Report) by 4.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,300 shares of the company’s stock after selling 100 shares during the quarter. Blume Capital Management Inc.’s holdings in Merck & Co., Inc. were worth $303,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Wellington Management Group LLP raised its stake in Merck & Co., Inc. by 3.8% during the 4th quarter. Wellington Management Group LLP now owns 85,595,999 shares of the company’s stock worth $9,331,676,000 after buying an additional 3,153,333 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Merck & Co., Inc. by 14.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 36,682,866 shares of the company’s stock worth $3,966,029,000 after purchasing an additional 4,731,152 shares during the last quarter. Norges Bank bought a new stake in shares of Merck & Co., Inc. in the fourth quarter worth about $3,108,366,000. Royal Bank of Canada grew its stake in shares of Merck & Co., Inc. by 12.8% in the fourth quarter. Royal Bank of Canada now owns 14,972,074 shares of the company’s stock worth $1,632,255,000 after purchasing an additional 1,696,151 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its holdings in Merck & Co., Inc. by 1.7% in the fourth quarter. Fisher Asset Management LLC now owns 13,566,968 shares of the company’s stock worth $1,479,071,000 after buying an additional 228,578 shares during the period. 76.07% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have commented on MRK shares. Truist Financial raised their price objective on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Berenberg Bank raised their price objective on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a report on Monday, April 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 price objective on shares of Merck & Co., Inc. in a report on Tuesday, June 18th. Argus upgraded shares of Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday, June 5th. Finally, Wells Fargo & Company raised their price objective on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 27th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and a consensus price target of $133.00.

View Our Latest Stock Analysis on MRK

Merck & Co., Inc. Trading Up 0.2 %

Shares of MRK stock opened at $126.08 on Wednesday. Merck & Co., Inc. has a 1 year low of $99.14 and a 1 year high of $134.63. The firm has a fifty day moving average price of $128.99 and a 200-day moving average price of $125.39. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.25 and a quick ratio of 0.99. The company has a market cap of $319.34 billion, a price-to-earnings ratio of 140.09, a PEG ratio of 2.43 and a beta of 0.38.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its quarterly earnings data on Thursday, April 25th. The company reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.94 by $0.13. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The firm had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.21 billion. During the same quarter in the previous year, the firm posted $1.40 EPS. The company’s revenue for the quarter was up 8.9% compared to the same quarter last year. As a group, equities analysts predict that Merck & Co., Inc. will post 8.62 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, July 8th. Investors of record on Monday, June 17th were paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 2.44%. The ex-dividend date of this dividend was Monday, June 17th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 342.22%.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.